{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T23:01:27Z","timestamp":1781218887744,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd012112","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,3,8]],"date-time":"2017-03-08T00:00:00Z","timestamp":1488931200000}}],"reference-count":80,"publisher":"Wiley","issue":"3","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd012112.pub2","type":"journal-article","created":{"date-parts":[[2017,3,7]],"date-time":"2017-03-07T22:56:23Z","timestamp":1488927383000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Intravesical Bacillus Calmette-Gu\u00e9rin with interferon-alpha versus intravesical Bacillus Calmette-Gu\u00e9rin for treating non-muscle-invasive bladder cancer"],"prefix":"10.1002","volume":"2017","author":[{"given":"Andrew RH","family":"Shepherd","sequence":"first","affiliation":[{"name":"Royal Adelaide Hospital; Department of Urology; North Terrace Adelaide South Australia Australia 5000"},{"name":"The University of Adelaide; School of Medicine; Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Shepherd","sequence":"additional","affiliation":[{"name":"The University of Adelaide; ARCH: Australian Research Centre for Health of Women and Babies, Robinson Research Institute, Discipline of Obstetrics and Gynaecology; Adelaide South Australia Australia 5006"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas R","family":"Brook","sequence":"additional","affiliation":[{"name":"Royal Adelaide Hospital; Department of Urology; North Terrace Adelaide South Australia Australia 5000"},{"name":"The University of Adelaide; School of Medicine; Adelaide Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,8]]},"reference":[{"issue":"4","key":"10.1002\/14651858.CD012112.pub2-BIB0001|cit1","first-page":"257","article-title":"BCG vs BCG plus recombinant Alfa-Interferon 2b for superficial bladder TCC","volume":"67","author":"Bercovich","year":"1995","journal-title":"Archivio Italiano Di Urologia e Andrologia"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012112.pub2-BIB0002|cit2","first-page":"317","article-title":"BCG Pasteur F and recombinant interferon alpha 2b in the prophylaxis of recurrent superficial neoplasia of the bladder: Preliminary results of a randomized study","volume":"7","author":"Irianni","year":"1993","journal-title":"Acta Urologica Italica"},{"issue":"3","key":"10.1002\/14651858.CD012112.pub2-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2010.11.031","article-title":"NRAMP1 and hGPX1 gene polymorphism and response to bacillus Calmette-Guerin therapy for bladder cancer","volume":"59","author":"Chiong","year":"2011","journal-title":"European Urology"},{"issue":"6","key":"10.1002\/14651858.CD012112.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cncr.22503","article-title":"Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha","volume":"109","author":"Esuvaranathan","year":"2007","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD012112.pub2-BIB0005|cit5","first-page":"1","article-title":"Long term results of a double-blind randomised controlled trial of interferon alpha-2b and low dose BCG in patients with high risk non-muscle-invasive bladder cancer","volume":"113","author":"Esuvaranathan","year":"2014","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD012112.pub2-BIB0006|cit6","first-page":"e571","article-title":"Long term results of a double-blind randomized controlled trial of interferon alpha-2b and low dose BCG in patients with high risk non-muscle-invasive bladder cancer","volume":"1","author":"Esuvaranathan","year":"2014","journal-title":"Journal of Urology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012112.pub2-BIB0007|cit7","first-page":"A52","article-title":"BCG & interferon alpha: Defining its benefits & limitations in high risk non-muscle invasive urothelial carcinoma after long follow-up","volume":"17","author":"Esuvaranathan","year":"2010","journal-title":"International Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD012112.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1006\/clim.1998.4647","article-title":"Evaluation of lymphocytic responses after treatment with Bacillus Calmette-Guerin and interferon-alpha 2b for superficial bladder cancer","volume":"90","author":"Gan","year":"1999","journal-title":"Clinical Immunology"},{"key":"10.1002\/14651858.CD012112.pub2-BIB0009|cit9","first-page":"e381","article-title":"Natural resistance-associated macrophage protein 1 (NRAMP1) gene polymorphisms and response to bacillus calmette-guerin therapy in Asian non-muscle invasive bladder cancer patients","volume":"1","author":"Sng","year":"2015","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD012112.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000189679","article-title":"Autoimmune clinical manifestations following intravesical bacillus calmette-guerin and interferon alpha 2b immunotherapy for superficial bladder cancer","volume":"3","author":"Vasdev","year":"2009","journal-title":"Current Urology"},{"issue":"1","key":"10.1002\/14651858.CD012112.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"e1107","DOI":"10.1016\/S1569-9056(14)61087-3","article-title":"15-year outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma (NMIBC) treated with 5 weekly mitomycin C (MMC) instillations followed by monthly Bacillus-Calmette Guerin (BCG) or alternating BCG and interferon-alpha2b (IFN) instillations","volume":"13","author":"Jarvinen","year":"2014","journal-title":"European Urology Supplement"},{"issue":"4","key":"10.1002\/14651858.CD012112.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.eururo.2015.02.022","article-title":"Long-term outcome of patients with frequently recurrent non-muscle-invasive bladder carcinoma treated with one perioperative plus four weekly instillations of mitomycin C followed by monthly Bacillus Calmette-Guerin (BCG) or alternating BCG and interferon-alpha2b instillations: Prospective randomised finnbladder-4 study","volume":"68","author":"Jarvinen","year":"2015","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD012112.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0302-2838(02)00260-9","article-title":"Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma","volume":"42","author":"Kaasinen","year":"2002","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD012112.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-5347(05)67446-0","article-title":"Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma","volume":"164","author":"Kaasinen","year":"2000","journal-title":"Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD012112.pub2-BIB0016|cit15","first-page":"46","article-title":"Combined intravesical immunotherapy for non-muscle invasive bladder cancer","volume":"3","author":"Minich","year":"2009","journal-title":"Oncological Journal"},{"issue":"4","key":"10.1002\/14651858.CD012112.pub2-BIB0015|cit16","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S1569-9056(09)60647-3","article-title":"Intravesical therapy with bacillus calmette-guerin plus interferon-\u03b12B for non-muscle invasive bladder cancer","volume":"8","author":"Minich","year":"2009","journal-title":"European Urology Supplement"},{"issue":"5","key":"10.1002\/14651858.CD012112.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.juro.2010.06.147","article-title":"Bacillus Calmette-Guerin with or without interferon alpha-2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer","volume":"184","author":"Nepple","year":"2010","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD012112.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urologic Oncology"},{"issue":"3","key":"10.1002\/14651858.CD012112.pub2-BIB0019|cit19","first-page":"888","article-title":"Interim results from a national multicenter phase II trial of combination bacillus Calmette-Guerin plus interferon alfa-2b for superficial bladder cancer [Erratum appears in J Urol. 2004 Dec;172 (6 Pt 1):2485]","volume":"172","author":"O'Donnell","year":"2004","journal-title":"Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD012112.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU Guidelines on non-muscle-invasive urothelial carcinoma of the bladder: Update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD012112.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1002\/1096-9098(200007)74:3<181::AID-JSO3>3.0.CO;2-F","article-title":"Prospective phase II trial of alternating intravesical Bacillus Calmette-Gu\u00e9rin (BCG) and interferon alpha IIB in the treatment and prevention of superficial transitional cell carcinoma of the urinary bladder: preliminary results","volume":"74","author":"Bazarbashi","year":"2000","journal-title":"Journal of Surgical Oncology"},{"issue":"137","key":"10.1002\/14651858.CD012112.pub2-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"137ra72","DOI":"10.1126\/scitranslmed.3003586","article-title":"Preexisting BCG-specific T cells improve intravesical immunotherapy for bladder cancer","volume":"4","author":"Biot","year":"2012","journal-title":"Science Translational Medicine"},{"issue":"5","key":"10.1002\/14651858.CD012112.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0302-2838(02)00068-4","article-title":"Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies","volume":"41","author":"Brausi","year":"2002","journal-title":"European Urology"},{"issue":"6","key":"10.1002\/14651858.CD012112.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the International Bladder Cancer Group","volume":"186","author":"Brausi","year":"2011","journal-title":"Journal of Urology"},{"issue":"1","key":"10.1002\/14651858.CD012112.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.eururo.2013.07.021","article-title":"Side effects of Bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG","volume":"65","author":"Brausi","year":"2014","journal-title":"European Urology"},{"issue":"2","key":"10.1002\/14651858.CD012112.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/(SICI)1097-0215(20000415)86:2<289::AID-IJC21>3.0.CO;2-M","article-title":"Cigarette smoking and bladder cancer in men: a pooled analysis of 11 case-control studies","volume":"86","author":"Brennan","year":"2000","journal-title":"International Journal of Cancer. Journal International du Cancer"},{"issue":"2","key":"10.1002\/14651858.CD012112.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","article-title":"Epidemiology and risk factors of urothelial bladder cancer","volume":"63","author":"Burger","year":"2013","journal-title":"European Urology"},{"key":"10.1002\/14651858.CD012112.pub2-BIB0028|cit28","unstructured":"Cancer Research UK Bladder cancer key facts publications.cancerresearchuk.org\/downloads\/Product\/CS_KF_BLADDER.pdf"},{"key":"10.1002\/14651858.CD012112.pub2-BIB0029|cit29","unstructured":"Chou R Buckley D Fu R Gore JL Gustafson K Griffin J Emerging approaches to diagnosis and treatment of non-muscle-invasive bladder cancer. Comparative Effectiveness Review No. 153. (Prepared by the Pacific Northwest Evidence-based Practice Center under Contract No. 290-2012-00014-I.) AHRQ Publication No. 15(16)-EHC017-EF. Rockville, MD: Agency for Healthcare Research and Quality. October 2015 www.effectivehealthcare.ahrq.gov\/reports\/final.cfm"},{"issue":"3","key":"10.1002\/14651858.CD012112.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"170","DOI":"10.7555\/JBR.27.20130026","article-title":"Bladder cancer epidemiology and genetic susceptibility","volume":"27","author":"Chu","year":"2013","journal-title":"Journal of Biomedical Research"},{"key":"10.1002\/14651858.CD012112.pub2-BIB0031|cit31","unstructured":"Deeks JJ Higgins JPT Altman DG (editors) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012112.pub2-BIB0032|cit32","unstructured":"Thomson Reuters EndNote 2016"},{"issue":"6","key":"10.1002\/14651858.CD012112.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/cncr.22503","article-title":"Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha","volume":"109","author":"Esuvaranathan","year":"2007","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012112.pub2-BIB0034|cit34","first-page":"A52","article-title":"BCG & interferon alpha: Defining its benefits & limitations in high risk non-muscle invasive urothelial carcinoma after long follow-up","volume":"17","author":"Esuvaranathan","year":"2010","journal-title":"International Journal of Urology"},{"key":"10.1002\/14651858.CD012112.pub2-BIB0035|cit35","first-page":"1","article-title":"Long term results of a double-blind randomised controlled trial of interferon alpha-2b and low dose BCG in patients with high risk non-muscle-invasive bladder cancer","volume":"113","author":"Esuvaranathan","year":"2014","journal-title":"BJU International"},{"key":"10.1002\/14651858.CD012112.pub2-BIB0036|cit36","unstructured":"Ferlay J Soerjomataram I Ervik M Dikshit R Eser S Mathers C GLOBOCAN 2012 v1.0, Cancer incidence and mortality worldwide: IARC CancerBase No. 11. Lyon, France: International Agency for Research on Cancer; 2013 globocan.iarc.fr"},{"issue":"6-7","key":"10.1002\/14651858.CD012112.pub2-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/j.biochi.2007.04.006","article-title":"Interferon-\u03b1 and cancer: mechanisms of action and new perspectives of clinical use","volume":"89","author":"Ferrantini","year":"2007","journal-title":"Biochimie"},{"issue":"7","key":"10.1002\/14651858.CD012112.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1001\/jama.2011.1142","article-title":"Association between smoking and risk of bladder cancer among men and women","volume":"306","author":"Freedman","year":"2011","journal-title":"JAMA"},{"issue":"2","key":"10.1002\/14651858.CD012112.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1006\/clim.1998.4647","article-title":"Evaluation of lymphocytic responses after treatment with Bacillus Calmette-Guerin and interferon-alpha 2b for superficial bladder cancer","volume":"90","author":"Gan","year":"1999","journal-title":"Clinical Immunology"},{"issue":"5","key":"10.1002\/14651858.CD012112.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"e1001026","DOI":"10.1371\/journal.pmed.1001026","article-title":"Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: methodological overview","volume":"8","author":"Golder","year":"2011","journal-title":"PLoS Medicine"},{"key":"10.1002\/14651858.CD012112.pub2-BIB0041|cit41","unstructured":"McMaster University GRADEpro GDT: GRADEpro Guideline Development Tool 2015 (developed by Evidence Prime Inc.). Available from www.gradepro.org"},{"issue":"7651","key":"10.1002\/14651858.CD012112.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1136\/bmj.39490.551019.BE","article-title":"GRADE: what is \"quality of evidence\" and why is it important to clinicians?","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"4","key":"10.1002\/14651858.CD012112.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"issue":"11","key":"10.1002\/14651858.CD012112.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"7414","key":"10.1002\/14651858.CD012112.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1002\/14651858.CD012112.pub2-BIB0046|cit46","unstructured":"Higgins JPT Green S (editors) Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012112.pub2-BIB0047|cit47","unstructured":"Higgins JPT Altman DG Sterne JAC (editors) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD012112.pub2-BIB0048|cit48","unstructured":"Higgins JPT Deeks JJ Altman DG (editors) Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD012112.pub2-BIB0049|cit49","first-page":"317","article-title":"BCG Pasteur F and recombinant interferon alpha 2b in the prophylaxis of recurrent superficial neoplasia of the bladder: Preliminary results of a randomized study","volume":"7","author":"Irianni","year":"1993","journal-title":"Acta Urologica Italica"},{"issue":"4","key":"10.1002\/14651858.CD012112.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.urolonc.2005.11.026","article-title":"Final results from a national multicenter phase II trial of combination bacillus Calmette-Gu\u00e9rin plus interferon \u03b1-2B for reducing recurrence of superficial bladder cancer","volume":"24","author":"Joudi","year":"2006","journal-title":"Urologic Oncology"},{"issue":"1","key":"10.1002\/14651858.CD012112.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0022-5347(05)67446-0","article-title":"Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma","volume":"164","author":"Kaasinen","year":"2000","journal-title":"Journal of Urology"},{"issue":"6 Suppl 1","key":"10.1002\/14651858.CD012112.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"issue":"5","key":"10.1002\/14651858.CD012112.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/S1078-1439(03)00012-7","article-title":"Bacillus calmette-gu\u00e9rin plus interferon-\u03b12B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity","volume":"21","author":"Lam","year":"2003","journal-title":"Urologic Oncology"},{"issue":"7","key":"10.1002\/14651858.CD012112.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","article-title":"The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration","volume":"6","author":"Liberati","year":"2009","journal-title":"PLoS Medicine"},{"issue":"2","key":"10.1002\/14651858.CD012112.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/2042098611401129","article-title":"Comprehensive evaluations of the adverse effects of drugs: importance of appropriate study selection and data sources","volume":"2","author":"Loke","journal-title":"Therapeutic Advances in Drug Safety"},{"issue":"2","key":"10.1002\/14651858.CD012112.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.eururo.2004.03.017","article-title":"Non-invasive urothelial neoplasms: according to the most recent WHO classification","volume":"46","author":"Lopez-Beltran","year":"2004","journal-title":"European Urology"},{"issue":"4","key":"10.1002\/14651858.CD012112.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.4049\/jimmunol.162.4.2399","article-title":"IFN-\u03b1 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Gu\u00e9rin immunotherapy","volume":"162","author":"Luo","year":"1999","journal-title":"Journal of Immunology (Baltimore, Md.: 1950)"},{"issue":"2","key":"10.1002\/14651858.CD012112.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S0022-5347(17)58737-6","article-title":"Intracavitary Bacillus Calmette-Gu\u00e9rin in the treatment of superficial bladder tumors","volume":"116","author":"Morales","year":"1976","journal-title":"Journal of Urology"},{"issue":"4","key":"10.1002\/14651858.CD012112.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0022-5347(05)65757-6","article-title":"Salvage intravesical therapy with interferon-\u03b1 2b plus low dose bacillus Calmette-Gu\u00e9rin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Gu\u00e9rin alone previously failed","volume":"166","author":"O'Donnell","year":"2001","journal-title":"Journal of Urology"},{"issue":"6","key":"10.1002\/14651858.CD012112.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1016\/S0022-5347(05)65520-6","article-title":"Familial bladder cancer in the National Swedish Family Cancer Database","volume":"166","author":"Plna","year":"2001","journal-title":"Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD012112.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s00345-009-0383-3","article-title":"The present and future burden of urinary bladder cancer in the world","volume":"27","author":"Ploeg","year":"2009","journal-title":"World Journal of Urology"},{"issue":"2","key":"10.1002\/14651858.CD012112.pub2-BIB0062|cit62","first-page":"1790","article-title":"Management of bacillus Calmette-Gu\u00e9rin (BCG) refractory superficial bladder cancer: results with intravesical BCG and Interferon combination therapy","volume":"10","author":"Punnen","year":"2003","journal-title":"Canadian Journal of Urology"},{"key":"10.1002\/14651858.CD012112.pub2-BIB0063|cit63","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan) 2014"},{"issue":"3","key":"10.1002\/14651858.CD012112.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3109\/08916930903510880","article-title":"Recent advances on the immunomodulatory effects of IFN-\u03b1: implications for cancer immunotherapy and autoimmunity","volume":"43","author":"Rizza","year":"2010","journal-title":"Autoimmunity"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD012112.pub2-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1100\/tsw.2004.81","article-title":"Superficial bladder cancer therapy","volume":"4","author":"Schenkman","year":"2004","journal-title":"Scientific World Journal"},{"key":"10.1002\/14651858.CD012112.pub2-BIB0066|cit66","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JPT Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and \u2018Summary of findings' tables. In: Higgins JPT, Green S (editors), Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"issue":"5","key":"10.1002\/14651858.CD012112.pub2-BIB0067|cit67","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006885.pub2","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus epirubicin for Ta and T1 bladder cancer","author":"Shang","year":"2011","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD012112.pub2-BIB0068|cit68","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001986","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin in Ta and T1 bladder cancer","author":"Shelley","year":"2000","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012112.pub2-BIB0069|cit69","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD003231","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin versus mitomycin C for Ta and T1 bladder cancer","author":"Shelley","year":"2003","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012112.pub2-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ctrv.2009.12.005","article-title":"Intravesical therapy for superficial bladder cancer: a systematic review of randomised trials and meta-analyses","volume":"36","author":"Shelley","year":"2010","journal-title":"Cancer Treatment Reviews"},{"issue":"3","key":"10.1002\/14651858.CD012112.pub2-BIB0071|cit71","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012112","article-title":"Intravesical Bacillus Calmette-Gu\u00e9rin with interferon-alpha versus intravesical Bacillus Calmette-Gu\u00e9rin for treating non-muscle-invasive bladder cancer","author":"Shepherd","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD012112.pub2-BIB0072|cit72","volume-title":"TNM Classification of Malignant Tumors. UICC International Union Against Cancer","author":"Sobin","year":"November 2009"},{"issue":"6 Pt 1","key":"10.1002\/14651858.CD012112.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1097\/01.ju.0000125486.92260.b2","article-title":"A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials","volume":"171","author":"Sylvester","year":"2004","journal-title":"Journal of Urology"},{"issue":"3","key":"10.1002\/14651858.CD012112.pub2-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.eururo.2005.12.031","article-title":"Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials","volume":"49","author":"Sylvester","year":"2006","journal-title":"European Urology"},{"issue":"3","key":"10.1002\/14651858.CD012112.pub2-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","article-title":"Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy","volume":"56","author":"Rhijn","year":"2009","journal-title":"European Urology"},{"issue":"1","key":"10.1002\/14651858.CD012112.pub2-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1159\/000189679","article-title":"Autoimmune clinical manifestations following intravesical bacillus calmette-guerin and interferon alpha 2b immunotherapy for superficial bladder cancer","volume":"3","author":"Vasdev","year":"2009","journal-title":"Current Urology"},{"issue":"1","key":"10.1002\/14651858.CD012112.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1080\/00039896.1991.9937423","article-title":"Proportion of lung and bladder cancers in males resulting from occupation: a systematic approach","volume":"46","author":"Vineis","year":"1991","journal-title":"Archives of Environmental Health"},{"issue":"8","key":"10.1002\/14651858.CD012112.pub2-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.eursup.2007.01.028","article-title":"The treatment of non-muscle-invasive bladder cancer with intravesical chemotherapy and immunotherapy","volume":"6","author":"Whelan","year":"2007","journal-title":"European Urology Supplements"},{"issue":"3","key":"10.1002\/14651858.CD012112.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1016\/S0022-5347(01)61832-9","article-title":"Effects of bacillus Calmette-Gu\u00e8rin and interferon alpha-2B on cytokine production in human bladder cancer cell lines","volume":"161","author":"Zhang","year":"1999","journal-title":"Journal of Urology"},{"key":"10.1002\/14651858.CD012112.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1186\/1471-2407-13-332","article-title":"Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies","volume":"13","author":"Zhu","year":"2013","journal-title":"BMC Cancer"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cochranelibrary.com\/cdsr\/doi\/10.1002\/14651858.CD012112.pub2\/epdf\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T14:37:13Z","timestamp":1692715033000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD012112.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Urology Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,3,8]]},"references-count":80,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd012112.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,8]]}}}